Surrozen, Inc./DE

SRZN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Revenue $3.5M $10.7M $0 $12.5M $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $29.4M $21.1M $27.2M $37.0M $40.2M
SG&A Expense $16.2M $15.1M $15.8M $19.8M $14.2M
Operating Income $-42.1M $-25.5M $-45.8M $-44.3M $-54.4M
Operating Margin -1,210.6% -239.7% -354.7%
Interest Expense
Pretax Income $-242.0M $-63.6M
Income Tax Expense $0 $0 $0 $0 $0
Net Income $-242.0M $-63.6M $-43.0M $-36.0M $-54.6M
Net Margin -6,960.8% -596.6% -288.0%
EPS (Basic) $-32.37 $-7.22 $-7.11 $-5.19 $-0.74
EPS (Diluted) $-32.37 $-7.22 $-7.11 $-5.19 $-0.74
Shares Outstanding (Basic) 7.5K 8.8K 6.1K 6.9K 74.1K
Shares Outstanding (Diluted) 7.5K 8.8K 6.1K 6.9K 74.1K
Dividends Per Share